Di Leo, Angelo
O’Shaughnessy, Joyce
Sledge, George W. Jr.
Martin, Miguel
Lin, Yong
Frenzel, Martin
Hardebeck, Molly C.
Smith, Ian C.
Llombart-Cussac, Antonio
Goetz, Matthew P.
Johnston, Stephen
Article History
Received: 13 July 2018
Accepted: 13 November 2018
First Online: 18 December 2018
Competing interests
: A.D.L. has been a consultant/independent contractor for Amgen, Roche, Novartis, Pfizer, AstraZeneca, Eli Lilly and Company, Pierre Fabre, Bayer, Celgene, Puma Biotechnology, and Daichii-Sankyo; has received grant/research support from Novartis, Pfizer, and AstraZeneca; honorarium from Roche, Novartis, Pfizer, AstraZeneca, Genomic Health, Eisai, Eli Lilly and Company, Pierre Fabre, Bayer, Celgene, and Daichii-Sankyo; and received travel/accommodations/expenses from Roche, Novartis, Pfizer, AstraZeneca, Eisai, Eli Lilly and Company, Pierre Fabre, Bayer, Celgene, Puma Biotechnology, and Daichii-Sankyo. J.O.S. has been a consultant/independent contractor for Novartis, Pfizer, AstraZeneca, and Eli Lilly and Company; has received honorarium from Novartis, Pfizer, AstraZeneca, and Eli Lilly and Company; and received travel/accommodations/expenses from Eli Lilly and Company. G.W.S. has been an advisor/board member for Symphogen, Radius Health, Taiho Pharmaceutical, and Syndax; has received grant/research support from Roche; honorarium from Symphogen; travel/accommodations/expenses from Radius Health, Taiho Pharmaceutical, and Synaffix; and is a stock shareholder in Syndax. M.M. has received speakers honoraria or honoraria for participation in Advisory Boards from AstraZeneca, Novartis, Roche-Genentech, Pfizer, Glaxo, Pharmamar, Taiho Oncology and Eli Lilly and Company, and research grants from Novartis and Roche. Y.L. is a full-time employee and stock shareholder of Eli Lilly and Company. M.F. is a full-time employee and stock shareholder of Eli Lilly and Company. M.C.H. is a full-time employee and stock shareholder of Eli Lilly and Company. I.C.S. is a full-time employee, stock shareholder, and patent holder of Eli Lilly and Company. A.L.-C. has been an advisor/consultant for Novartis, Pfizer, Roche, Eli Lilly and Company, AstraZeneca, and Eisai; has received grant/research support from Pfizer, AstraZeneca, Tesaro, Pierre Fabre, and Roche; honorarium from Roche; stock, patents and intellectual property with MedSIR; travel/accommodations/expenses from Roche, Pfizer, and Celgene. M.P.G. has been a consultant for Eli Lilly and Company, bioTheranostics, Novartis, Genomic Health, Eisai, Biovica, and Sermonix; and received research funding from Eli Lilly and Company, and Pfizer. S.J. has been in the speaker’s bureau of OBI and Puma; has been a consultant/independent contractor for Novartis, Pfizer, AstraZeneca, OBI, and Eli Lilly and Company; and has received grant/research support from Pfizer.